Reviewing Meihua International Medical Technologies (NASDAQ:MHUA) & Tandem Diabetes Care (NASDAQ:TNDM)

Meihua International Medical Technologies (NASDAQ:MHUAGet Free Report) and Tandem Diabetes Care (NASDAQ:TNDMGet Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Insider & Institutional Ownership

1.2% of Meihua International Medical Technologies shares are owned by institutional investors. 66.6% of Meihua International Medical Technologies shares are owned by insiders. Comparatively, 2.5% of Tandem Diabetes Care shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for Meihua International Medical Technologies and Tandem Diabetes Care, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Meihua International Medical Technologies 0 0 0 0 N/A
Tandem Diabetes Care 1 6 5 0 2.33

Tandem Diabetes Care has a consensus target price of $36.36, indicating a potential upside of 2.69%. Given Tandem Diabetes Care’s higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than Meihua International Medical Technologies.

Volatility & Risk

Meihua International Medical Technologies has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Earnings and Valuation

This table compares Meihua International Medical Technologies and Tandem Diabetes Care’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Meihua International Medical Technologies $103.35 million 0.18 $6.24 million N/A N/A
Tandem Diabetes Care $747.72 million 3.11 -$222.61 million ($3.44) -10.29

Meihua International Medical Technologies has higher earnings, but lower revenue than Tandem Diabetes Care.

Profitability

This table compares Meihua International Medical Technologies and Tandem Diabetes Care’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Meihua International Medical Technologies N/A N/A N/A
Tandem Diabetes Care -29.77% -31.48% -10.75%

Summary

Meihua International Medical Technologies beats Tandem Diabetes Care on 6 of the 11 factors compared between the two stocks.

About Meihua International Medical Technologies

(Get Free Report)

Meihua International Medical Technologies Co., Ltd. engages in the manufacture, sells, and marketing of medical consumables in the People's Republic of China. The company offers class I, II, and III disposable medical devices. Its products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles, as well as electronic pumps. The company also distributes disposable medical devices sourced from other manufacturers to customers in China. In addition, it offers COVID-19 products comprising disposable medical masks. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.

About Tandem Diabetes Care

(Get Free Report)

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Receive News & Ratings for Meihua International Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meihua International Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.